To order this detailed 250+ page report, please visit this -https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html
Key Inclusions
§
A detailed assessment
of the current market landscape, including information on type of developer
(industry, non-industry, industry / non-industry), phase of development (phase
I, phase I/II, phase II, phase II/III, phase III and preregistration) of lead
candidates, route of administration (intramuscular, intranasal, oral,
intradermal, subcutaneous, intravenous and others), type of vaccine API (live,
attenuated vaccine, recombinant vaccine, conjugate vaccine, inactivated
vaccine, DNA vaccine, peptide vaccine, subunit vaccine, mRNA vaccine, toxoid
vaccine and others), dosage form (ready to use liquid, lyophilized powder,
nasal spray, capsule and tablet), dosage (single dose, 2 doses, 3 doses, 4
doses, 5 doses and 6 doses), target disease indication and target patient population
(children, adults and seniors).
§
A competitiveness
analysis of preventive vaccine developers, taking into consideration supplier
strength (based on company size and its experience in this field) and pipeline
strength (based on the number of clinical-stage vaccine candidates, highest
phase of development, number of compatible routes of administration, number of
indications evaluated and target patient population).
§
Elaborate profiles of
the key preventive vaccine developers (shortlisted based on a proprietary
criterion) across North America, Europe and Asia Pacific. Each profile includes
a brief overview of the company, its year of establishment, location of
headquarters, number of employees and financial information (if available). In
addition to this, the profile includes information on the various
clinical-stage vaccine candidates developed by the company. Further, we have
provided the recent developments of the company and an informed future outlook.
§
A detailed analysis
of more than 1,400 completed, ongoing and planned clinical studies of
preventive vaccines, highlighting prevalent trends across various relevant
parameters, such as trial registration year, phase of development, trial
recruitment status, study design, trial focus area, type of preventive vaccine
(based on pathogen), target disease indication(s), type of sponsor / collaborator, leading
industry sponsors / collaborators (in terms of number of trials conducted),
enrolled patients population and regional distribution.
§
An overview of the ongoing
vaccine development initiatives for complex conditions, such as COVID-19, Ebola
virus disease, HIV/AIDS, malaria and zika virus infection, including
information on disease, its global burden, current treatment landscape and
preventive vaccine research landscape. Further, we have provided the
information on investments made and recent developments in the domain.
§
An analysis of the
investments made in this domain, during the period between 2015 and 2020 (till
March), including seed financing, venture capital financing, debt financing,
grants, capital raised from IPOs and subsequent offerings, at various stages of
development in companies that are engaged in developing preventive vaccines.
§
A case study on
contract manufacturing landscape for vaccines, featuring a comprehensive list
of active CMOs and analyses based on a number of parameters, such as year of
establishment, company size, scale of operation (preclinical, clinical and
commercial), geographical location, number of vaccine manufacturing facilities,
types of services offered (cell / virus banking, analytical development /
testing, formulation, process development, fill / finish and regulatory
filings), type of expression systems used for vaccine production (mammalian,
microbial and others) and type of vaccine manufactured.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§
Route of Administration
§ Intramuscular
§ Subcutaneous
§ Oral
§ Intravenous
§ Others
§
Type of Vaccine
§ Pneumococcal
Conjugate Vaccine
§ Human
Papilloma Virus Vaccine
§ Rotavirus
Vaccine
§ Influenza
Vaccine
§ MMR
Vaccine
§ Tetanus
and Diphtheria Booster Vaccine
§ Varicella
Vaccine
§ DTaP-Hib-IPV
Vaccine
§ DTaP-HepB-Hib-IPV
Vaccine
§ Others
§ Type
of Vaccine API
§ Live,
Attenuated Vaccine
§ Inactivated
Vaccine
§ Conjugate
Vaccine
§ Subunit
Vaccine
§ Toxoid
Vaccine
§ Others
§ Target
Patient Population
§ Pediatric
Patients
§ Adults
§ Key
Players
§ GlaxoSmithKline
§ Merck
§ Sanofi
Pasteur
§ Pfizer
§ Emergent
BioSolutions
§ CSL
§ Others
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/318/request-sample.html
Key Questions Answered
§
Who are the leading developers of preventive vaccines?
§
How big is the
development pipeline and which new indications are coming in focus?
§
Who are the key investors
in the preventive vaccines market?
§
What is the impact of COVID-19 on the demand for preventive
vaccines?
§
Which are the key /
emerging CMOs, in different regions, that you can reach out to for your vaccine
manufacturing requirements?
§
How is the current
and future opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
§
Novel
coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in
Development
§
Novel
Vaccine Delivery Devices Market, 2019-2030 [COVID-19 SERIES]
§
Vaccine
Contract Manufacturing Market (2nd Edition), 2019-2030 [COVID-19 SERIES]
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com